TNF Pharmaceuticals Inc (NASDAQ:TNFA) currently has a daily average trading volume of 178.97K but it saw 2734084 shares traded in last market. With a market cap of 2.91M USD, the company’s current market price of $1.05 came falling about -9.83 while comparing to the previous closing price of $1.17. In past 52 weeks, the stock remained buoying in the range of price level as high as $5.29 and as low as $1.05. In the recent trading on the day, stock has struck highest price mark of $1.0 while lowest mark touched by it was $1.3799.
Taking a look at 20-day trading activity of TNF Pharmaceuticals Inc (TNFA) gives us an average price of $1.2012, while its current price level is -80.05% below from 52-week high level whereas it is 0.48% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2385 while that of 200 days or SMA-200 reads an average of $1.7313. A closer look into the stock’s movement over the week reveals that its volatility is standing at 13.36% during that period while stretching the period over a month that decreases to 10.54%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 40.20 which implies that the stock is in neutral territory.
Over the week, TNFA’s stock price is moving -7.46% down while it is -18.22% when we observe its performance for the past one month. Year-to-date it is -8.26% down and over the past year, the stock is showing a downside performance of -77.56%.
The company is expected to be releasing its next quarterly report in February, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, TNF Pharmaceuticals Inc’s total number of outstanding shares is 2.76M with 5.12% of that held by the insiders while 44.10% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -169.55% and return on equity (ROE) at -142.68%. Stock’s beta reads 2.17. Stock has a price to book (P/B) ratio of 0.16. Its return on asset (ROA) is -103.16% on average.
